TORONTO – The Probuphine implant developed by San Francisco's Titan Pharmaceuticals Inc. comprises match-stick sized rods inserted into the patient's upper arm. It aims to provide an ongoing low dose of buprenorphine and help recovering addicts stick to their daily medication regimens. Montreal-based Knight Therapeutics Inc., which enjoys exclusive Canadian distribution rights for the implant, is gearing up for cross-country sales, notably in British Columbia, the province hardest hit by opioid abuse and fatalities.